Search Results

You are looking at 21 - 30 of 111 items for :

  • "aromatase inhibitor" x
Clear All
Full access

7 7 2 2 Personalized Medicine and Breast Cancer Care Burstein Harold J. MD, PhD 2 2009 7 7 2 2 109 109 109 109 10.6004/jnccn.2009.0010 Predictors and Temporal Trends of Adjuvant Aromatase Inhibitor Use in Breast Cancer Svahn Tiffany

Full access

B. MD Sheldon David G. MD 4 2003 1 1 2 2 207 207 212 212 10.6004/jnccn.2003.0019 The Aromatase Inhibitors as Adjuvant Therapy for Hormone Receptor-Positive Breast Cancer Ligibel Jennifer A. MD Winer Eric P. MD 4 2003 1

Full access

William J. Gradishar

advanced breast cancer after disease progression on nonsteroidal aromatase inhibitors (AIs). 3 - 5 For instance, the phase III SoFEA trial revealed that combining fulvestrant with exemestane was no better than either fulvestrant alone or exemestane alone

Full access

Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel

-free and overall survival. 7 The effectiveness of aromatase inhibitors in the treatment of metastatic breast cancer led to a number of trials incorporating them into the adjuvant therapy of postmenopausal women with early-stage hormone receptor

Full access

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias and Giovanni Casazza

during adjuvant aromatase inhibitor therapy for breast cancer . Clin Cancer Res 2008 ; 14 : 6336 – 6342 . 16. Mincey BA Dentchev T Sloan JA . N03CC—a randomized, controlled, open-label trial of upfront vs. delayed zoledronic acid for

Full access

William J. Gradishar, Benjamin O. Anderson, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Robert S. Miller, Mark Pegram, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead and Rashmi Kumar

breast cancer should be treated similarly to postmenopausal women, except that the use of aromatase inhibitors is ineffective without concomitant suppression of testicular steroidogenesis. 22 , 23 Patient preference is a major component of the decision

Full access

Erin Currin, Lanell M. Peterson, Erin K. Schubert, Jeanne M. Link, Kenneth A. Krohn, Robert B. Livingston, David A. Mankoff and Hannah M. Linden

promising data emerging regarding aromatase inhibitors 9 and concern about endometrial side effects, she was switched from tamoxifen to anastrozole after a year of treatment. The patient experienced a sustained response to endocrine therapy for 1.5 years

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff and Richard Zellars

, patient age, and menopausal status. Breast cancer does occur in men, and treatment should be similar to that for postmenopausal women, except that aromatase inhibitors are ineffective without concomitant suppression of testicular steroidogenesis. 27 , 28

Full access

Aromatase Inhibitors Charlson John a b MD Smith Elizabeth C. b PhD Smallwood Alicia J. b BA, BM Laud Purushottam W. c PhD Neuner Joan M. b d MD, MPH 7 2016 14 14 7 7 875 875 880 880 0140875 10.6004/jnccn.2016

Full access

Harold J. Burstein

direct bearing on the treatment plans for breast cancer survivors. These include data on switching endocrine therapies between years 2 and 3 after diagnosis; use of extended adjuvant endocrine therapy with aromatase inhibitors; introduction of adjuvant